Skip to main content

Integrated transcriptomic analysis reveals immune signatures distinguishing persistent versus resolving outcomes in MRSA bacteremia.

Publication ,  Journal Article
Parmar, R; Pickering, H; Ahn, R; Rossetti, M; Gjertson, DW; Ruffin, F; Chan, LC; Fowler, VG; Yeaman, MR; Reed, EF; MRSA Systems Immunology Group
Published in: Front Immunol
2024

INTRODUCTION: Staphylococcus aureus bacteremia (SAB) is a life-threatening infection particularly involving methicillin-resistant S. aureus (MRSA). In contrast to resolving MRSA bacteremia (RB), persistent MRSA bacteremia (PB) blood cultures remain positive despite appropriate antibiotic treatment. Host immune responses distinguishing PB vs. RB outcomes are poorly understood. Here, integrated transcriptomic, IL-10 cytokine levels, and genomic analyses sought to identify signatures differentiating PB vs. RB outcomes. METHODS: Whole-blood transcriptomes of propensity-matched PB (n=28) versus RB (n=30) patients treated with vancomycin were compared in one independent training patient cohort. Gene expression (GE) modules were analyzed and prioritized relative to host IL-10 cytokine levels and DNA methyltransferase-3A (DNMT3A) genotype. RESULTS: Differential expression of T and B lymphocyte gene expression early in MRSA bacteremia discriminated RB from PB outcomes. Significant increases in effector T and B cell signaling pathways correlated with RB, lower IL-10 cytokine levels and DNMT3A heterozygous A/C genotype. Importantly, a second PB and RB patient cohort analyzed in a masked manner demonstrated high predictive accuracy of differential signatures. DISCUSSION: Collectively, the present findings indicate that human PB involves dysregulated immunity characterized by impaired T and B cell responses associated with excessive IL-10 expression in context of the DNMT3A A/A genotype. These findings reveal distinct immunologic programs in PB vs. RB outcomes, enable future studies to define mechanisms by which host and/or pathogen drive differential signatures and may accelerate prediction of PB outcomes. Such prognostic assessment of host risk could significantly enhance early anti-infective interventions to avert PB and improve patient outcomes.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Front Immunol

DOI

EISSN

1664-3224

Publication Date

2024

Volume

15

Start / End Page

1373553

Location

Switzerland

Related Subject Headings

  • Transcriptome
  • Staphylococcal Infections
  • Middle Aged
  • Methicillin-Resistant Staphylococcus aureus
  • Male
  • Interleukin-10
  • Humans
  • Gene Expression Profiling
  • Female
  • DNA Methyltransferase 3A
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Parmar, R., Pickering, H., Ahn, R., Rossetti, M., Gjertson, D. W., Ruffin, F., … MRSA Systems Immunology Group, . (2024). Integrated transcriptomic analysis reveals immune signatures distinguishing persistent versus resolving outcomes in MRSA bacteremia. Front Immunol, 15, 1373553. https://doi.org/10.3389/fimmu.2024.1373553
Parmar, Rajesh, Harry Pickering, Richard Ahn, Maura Rossetti, David W. Gjertson, Felicia Ruffin, Liana C. Chan, et al. “Integrated transcriptomic analysis reveals immune signatures distinguishing persistent versus resolving outcomes in MRSA bacteremia.Front Immunol 15 (2024): 1373553. https://doi.org/10.3389/fimmu.2024.1373553.
Parmar R, Pickering H, Ahn R, Rossetti M, Gjertson DW, Ruffin F, et al. Integrated transcriptomic analysis reveals immune signatures distinguishing persistent versus resolving outcomes in MRSA bacteremia. Front Immunol. 2024;15:1373553.
Parmar, Rajesh, et al. “Integrated transcriptomic analysis reveals immune signatures distinguishing persistent versus resolving outcomes in MRSA bacteremia.Front Immunol, vol. 15, 2024, p. 1373553. Pubmed, doi:10.3389/fimmu.2024.1373553.
Parmar R, Pickering H, Ahn R, Rossetti M, Gjertson DW, Ruffin F, Chan LC, Fowler VG, Yeaman MR, Reed EF, MRSA Systems Immunology Group. Integrated transcriptomic analysis reveals immune signatures distinguishing persistent versus resolving outcomes in MRSA bacteremia. Front Immunol. 2024;15:1373553.

Published In

Front Immunol

DOI

EISSN

1664-3224

Publication Date

2024

Volume

15

Start / End Page

1373553

Location

Switzerland

Related Subject Headings

  • Transcriptome
  • Staphylococcal Infections
  • Middle Aged
  • Methicillin-Resistant Staphylococcus aureus
  • Male
  • Interleukin-10
  • Humans
  • Gene Expression Profiling
  • Female
  • DNA Methyltransferase 3A